Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib Combinations in Advanced Solid Tumors
NCT06161558Phase 1Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jul 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of erlotinib in solid tumor (2 arms), sponsored by National Cancer Institute. Primary endpoint: Safety, tolerability, and maximum tolerated dose (MTD) at 30 months. Planned start Jul 2025; status: withdrawn.
02
Drugs
erlotinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06161558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161558.